AQN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AQN is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some positive setup signals, but the latest quarter fundamentals are weak, analyst opinions are mixed, and there is no strong proprietary buy signal to justify an immediate purchase. Best direct call: hold off and do not buy now.
AQN is showing a modestly constructive short-term trend, but not a strong breakout setup. Price closed at 6.39, slightly above the pivot at 6.282 and near resistance at R1 6.381, which means the stock is pushing into resistance rather than breaking away cleanly. Moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports the medium-term trend. MACD histogram is positive at 0.00791, but it is contracting, so momentum is weakening. RSI_6 at 47.79 is neutral, confirming no strong buy signal from momentum. Overall, the chart is mildly bullish but not compelling enough for an immediate long-term entry.
Recent analyst support improved after Barclays initiated coverage with an Overweight rating and $7 target, calling AQN a cheap turnaround story. Raymond James also upgraded the stock to Outperform with a $7.25 target, citing improving execution, cost discipline, and better regulatory outcomes. Hedge funds are buying, with buying amount up 241.67% over the last quarter. The stock also has a positive short-term pattern estimate, with an 80% chance of rising 1.11% next day, 4.5% next week, and 6.34% next month. Post-market change was also positive at 1.75%, which adds near-term tone support.
The main negative is weak earnings quality in the latest quarter: revenue rose 7.84% YoY in 2025/Q4, but net income fell 109.73% and EPS dropped 107.69%, showing margin and profitability pressure. News also points to a cautious upcoming Q1 outlook with consensus EPS expected to decline 21.4% YoY to $0.11, while revenue expectations are only moderate at $713.69 million. CIBC kept only a Neutral rating and raised its target modestly to $6.50, and prior commentary from CIBC and TD highlighted the damage from the reduced 2027 earnings outlook due to tax headwinds. Insider trading is neutral, and there is no recent congress trading data to add conviction.
Latest reported quarter: 2025/Q4. Revenue increased to $630.7 million, up 7.84% YoY, which is a positive top-line trend. However, net income fell to $18.4 million, down 109.73% YoY, and EPS dropped to $0.02, down 107.69% YoY, showing that earnings quality weakened significantly despite revenue growth. Gross margin slipped slightly to 54.46%, suggesting limited profitability improvement. The next quarter being reported is Q1 2023 earnings in the provided calendar/news context, with consensus EPS of $0.11 and revenue of $713.69 million, indicating cautious expectations.
Analyst sentiment is mixed-to-positive. Recent positives include Barclays initiating Overweight with a $7 target and Raymond James upgrading to Outperform with a $7.25 target, both arguing the turnaround and regulated utility refocus are improving. On the cautious side, CIBC kept Neutral and only nudged the target to $6.50, while TD kept Hold and cut its target to $6 after the reduced 2027 earnings outlook tied to tax headwinds. JPMorgan previously stayed Neutral. Wall Street’s pro view is that AQN is cheap, improving operationally, and better positioned after the renewables sale; the con view is that earnings guidance was cut, investor confidence was hurt, and profitability remains uneven.
